US-based regenerative medicine company Carmell Therapeutics is developing a patented technology that enables the delivery of growth factors directly to injured sites in order to promote the healing of bone and soft tissue, as well as reduce infections. The company’s plasma-based bioactive material (PBM) technology derives from Carnegie Mellon University in Pittsburgh, Pennsylvania, from which Carmell spun out in 2007. The technology has time-release capabilities to accelerate healing, with the active biologics released over different time periods as the PBM biodegrades at the injured site.Read More >
Pittsburgh Technology Council Names Category Leaders on October 12, 2017
PITTSBURGH, PA – Carmell Therapeutics, a privately-owned biotechnology company focused on the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs), today announced that the Pittsburgh Technology Council has named it a Tech 50 Category Leader in the Innovator of the Year: Life Sciences Category.Read More >
Harvard John A. Paulson School of Engineering and Applied Sciences website.
A physician can make a positive impact on every patient, but an engineer who develops the right biomedical device could potentially help millions of people suffering from an illness or injury.
Alumna Stephanie Kladakis, S.B. ’96, is that engineer.Read More >